Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: Major prognostic impact of proapoptotic BAX

British Journal of Cancer

Volumn 96, Issue 9, 2007, Pages 1409-1418

  Nehls, O ^a   Okech, T ^a   Hsieh, C J ^a   Enzinger, T ^a   Sarbia, M ^b   Borchard, F ^c   Gruenagel, H H ^d   Gaco, V ^a   Hass, H G ^a   Arkenau, H T ^e   Hartmann, J T ^a   Porschen, R ^e   Gregor, M ^a   Klump, B ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c Department of Pathology ^*  (Germany)

^d Evangelic Hospital   (Germany)

^e Central Hospital Bremen Ost   (Germany)

Author keywords

Adjuvant chemotherapy; BAT26; BAX; Bcl 2; Colon carcinoma; Microsatellite instability; p53 BAX pathway; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BIVARIATE ANALYSIS; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247577671     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603728     Document Type: Article

References (8)

1. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Blum Jr PA, Stemmerman G, Wells JD, Macdonald JS, Meyskens Jr FL (1998) Ki-ras mutation and p53 overexpression predict the clinical behaviour of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58: 1149-1158
2. Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R, Arbeitsgemeinschaft gastrointestinale Onkologie (2003) Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol 14: 395-399
3. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland SR (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131
4. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B (2001) P53 alterations and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7: 1343-1349
5. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
6. Garrity MM, Burgart LJ, and Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connel MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE, North Central Cancer Treatment Group (2004) Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 22: 1572-1582
7. Greene FL, Stewart AH, Norton HJ (2002) A new TNM staging strategy for node positive (stage III) colon cancer: an analysis of 50042 patients. Ann Surg 236: 416-421
8. Grizzle EG, Manne U, Weiss HL, Jhala N, Talley L (2002) Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 and p27kip1. Int J Cancer 97: 403-409